MX341464B - Estabilización de fsh. - Google Patents
Estabilización de fsh.Info
- Publication number
- MX341464B MX341464B MX2013000681A MX2013000681A MX341464B MX 341464 B MX341464 B MX 341464B MX 2013000681 A MX2013000681 A MX 2013000681A MX 2013000681 A MX2013000681 A MX 2013000681A MX 341464 B MX341464 B MX 341464B
- Authority
- MX
- Mexico
- Prior art keywords
- stabilization
- salts
- fsh
- pharmaceutically acceptable
- addition
- Prior art date
Links
- 230000006641 stabilisation Effects 0.000 title abstract 3
- 238000011105 stabilization Methods 0.000 title abstract 3
- 238000009472 formulation Methods 0.000 abstract 2
- 239000000203 mixture Substances 0.000 abstract 2
- 150000003839 salts Chemical class 0.000 abstract 2
- 229910052783 alkali metal Inorganic materials 0.000 abstract 1
- -1 alkali metal cations Chemical class 0.000 abstract 1
- 239000007788 liquid Substances 0.000 abstract 1
- 159000000001 potassium salts Chemical class 0.000 abstract 1
- 159000000000 sodium salts Chemical class 0.000 abstract 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/16—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- A61K38/17—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- A61K38/22—Hormones
- A61K38/24—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g. HCG; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/02—Inorganic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/10—Alcohols; Phenols; Salts thereof, e.g. glycerol; Polyethylene glycols [PEG]; Poloxamers; PEG/POE alkyl ethers
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/08—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing oxygen, e.g. ethers, acetals, ketones, quinones, aldehydes, peroxides
- A61K47/12—Carboxylic acids; Salts or anhydrides thereof
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/20—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing sulfur, e.g. dimethyl sulfoxide [DMSO], docusate, sodium lauryl sulfate or aminosulfonic acids
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
- A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
- A61K47/26—Carbohydrates, e.g. sugar alcohols, amino sugars, nucleic acids, mono-, di- or oligo-saccharides; Derivatives thereof, e.g. polysorbates, sorbitan fatty acid esters or glycyrrhizin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/0012—Galenical forms characterised by the site of application
- A61K9/0019—Injectable compositions; Intramuscular, intravenous, arterial, subcutaneous administration; Compositions to be administered through the skin in an invasive manner
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/08—Solutions
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P15/00—Drugs for genital or sexual disorders; Contraceptives
- A61P15/08—Drugs for genital or sexual disorders; Contraceptives for gonadal disorders or for enhancing fertility, e.g. inducers of ovulation or of spermatogenesis
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07K—PEPTIDES
- C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
- C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
- C07K14/575—Hormones
- C07K14/59—Follicle-stimulating hormone [FSH]; Chorionic gonadotropins, e.g.hCG [human chorionic gonadotropin]; Luteinising hormone [LH]; Thyroid-stimulating hormone [TSH]
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Epidemiology (AREA)
- Endocrinology (AREA)
- Engineering & Computer Science (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Reproductive Health (AREA)
- Organic Chemistry (AREA)
- Oil, Petroleum & Natural Gas (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Gastroenterology & Hepatology (AREA)
- Zoology (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Molecular Biology (AREA)
- Biochemistry (AREA)
- Immunology (AREA)
- Inorganic Chemistry (AREA)
- Dermatology (AREA)
- Biophysics (AREA)
- Genetics & Genomics (AREA)
- Toxicology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Pregnancy & Childbirth (AREA)
- Gynecology & Obstetrics (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Peptides Or Proteins (AREA)
- Magnetic Resonance Imaging Apparatus (AREA)
- Fats And Perfumes (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
Abstract
La presente invención se refiere a al campo de la estabilización de formulaciones de FSH, en particular formulaciones líquidas de FSH. La estabilización se logra por medio de la adición de sales que comprenden cationes de metales alcalinos farmacéuticamente aceptables, en modalidades preferidas por medio de la adición de sales farmacéuticamente aceptables, es decir, sales de sodio o sales de potasio. La figura más representativa de la invención es la número 1.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
EP10171428A EP2417982A1 (en) | 2010-07-30 | 2010-07-30 | Stabilization of gonadotropins |
PCT/EP2011/062986 WO2012013742A2 (en) | 2010-07-30 | 2011-07-28 | Stabilization of fsh |
Publications (2)
Publication Number | Publication Date |
---|---|
MX2013000681A MX2013000681A (es) | 2013-02-27 |
MX341464B true MX341464B (es) | 2016-08-22 |
Family
ID=43216624
Family Applications (2)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2013000681A MX341464B (es) | 2010-07-30 | 2011-07-28 | Estabilización de fsh. |
MX2016010733A MX356951B (es) | 2010-07-30 | 2011-07-28 | Estabilizacion de fsh. |
Family Applications After (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
MX2016010733A MX356951B (es) | 2010-07-30 | 2011-07-28 | Estabilizacion de fsh. |
Country Status (27)
Country | Link |
---|---|
US (3) | US8993732B2 (es) |
EP (3) | EP2417982A1 (es) |
JP (3) | JP5860047B2 (es) |
KR (2) | KR101991756B1 (es) |
CN (2) | CN105106939A (es) |
AR (1) | AR082776A1 (es) |
AU (1) | AU2011284702C1 (es) |
BR (1) | BR112013002312B1 (es) |
CA (1) | CA2805864A1 (es) |
DK (1) | DK2598160T3 (es) |
ES (1) | ES2623634T3 (es) |
HR (1) | HRP20170386T1 (es) |
HU (1) | HUE033592T2 (es) |
IL (2) | IL223821A (es) |
JO (1) | JO3229B1 (es) |
LT (1) | LT2598160T (es) |
MX (2) | MX341464B (es) |
NZ (2) | NZ606366A (es) |
PL (1) | PL2598160T3 (es) |
PT (1) | PT2598160T (es) |
RS (1) | RS55772B1 (es) |
RU (1) | RU2574012C2 (es) |
SA (1) | SA114350786B1 (es) |
SI (1) | SI2598160T1 (es) |
TW (1) | TWI439283B (es) |
WO (1) | WO2012013742A2 (es) |
ZA (1) | ZA201209497B (es) |
Families Citing this family (12)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
EP2417982A1 (en) * | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
JO3092B1 (ar) | 2011-08-08 | 2017-03-15 | Ferring Bv | مركب لتحفيز مسيطر عليه للمبيض |
WO2015075743A1 (en) * | 2013-11-12 | 2015-05-28 | Cadila Healthcare Limited | Formulation for gonadotropins |
CN105727260A (zh) * | 2016-02-03 | 2016-07-06 | 华侨大学 | 一种卵泡刺激素的长效制剂 |
GB201603280D0 (en) * | 2016-02-24 | 2016-04-13 | Ferring Bv | Stable liquid gonadotropin formulation |
FR3083089A1 (fr) * | 2018-06-29 | 2020-01-03 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
CA3084689A1 (fr) | 2017-12-07 | 2019-06-13 | Adocia | Solution injectable a ph 7 comprenant au moins une insuline basale dont le pi est compris entre 5,8 et 8,5 et un co-polyaminoacide porteur de charges carboxylates et de radicaux hydrophobes |
JP2021505607A (ja) | 2017-12-07 | 2021-02-18 | アドシア | 5.8〜8.5のpIを有する少なくとも1つの基礎インスリンならびにカルボキシレート電荷および疎水性ラジカルを有するコポリアミノ酸を含むpH7の注射溶液 |
FR3084584B1 (fr) * | 2018-08-03 | 2020-11-06 | Adocia | Solution injectable a ph 7 comprenant du glucagon humain et un compose amphiphile porteur de radicaux hydrophobes |
FR3084586B1 (fr) * | 2018-08-03 | 2020-11-06 | Adocia | Compositions sous forme d'une solution aqueuse injectable comprenant de l'amyline, un agoniste au recepteur de l'amyline ou un analogue d'amyline et un compose amphiphile porteur de radicaux hydrophobes |
JP7425459B2 (ja) | 2019-10-11 | 2024-01-31 | 株式会社シノテスト | 安定化されたhmgb1含有溶液 |
Family Cites Families (13)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
SU607001A1 (ru) * | 1976-01-14 | 1978-05-15 | Краснодарский Государственный Научно-Исследовательский И Проектный Институт Нефтяной Промышленности | Способ получени кислотного раствора |
DE69524456T2 (de) | 1995-03-21 | 2002-08-01 | Applied Research Systems | Flüssige hcg-formulierungen |
CZ297042B6 (cs) * | 1996-05-29 | 2006-08-16 | Delsitechoy | Dodávkové zarízení pro pomalé uvolnování biologicky úcinného cinidla, jeho pouzití a farmaceutický prostredek s jeho obsahem |
TW518235B (en) | 1997-01-15 | 2003-01-21 | Akzo Nobel Nv | A gonadotropin-containing pharmaceutical composition with improved stability on prolong storage |
US20030166525A1 (en) * | 1998-07-23 | 2003-09-04 | Hoffmann James Arthur | FSH Formulation |
JP4719357B2 (ja) * | 1998-07-23 | 2011-07-06 | アレス トレイディング ソシエテ アノニム | Fsh及びfsh変異体の製剤、製品及び方法 |
DK1740213T3 (da) * | 2004-04-07 | 2012-04-10 | Ares Trading Sa | Væskeformulering til væksthormoner |
KR101105871B1 (ko) * | 2005-09-27 | 2012-01-16 | 주식회사 엘지생명과학 | 인 난포자극호르몬의 안정한 용액 제형 |
TWI488640B (zh) | 2008-04-16 | 2015-06-21 | Ferring Int Ct Sa | 藥學製劑 |
CN101614748A (zh) * | 2008-06-25 | 2009-12-30 | 上海新波生物技术有限公司 | 促卵泡激素时间分辨免疫荧光分析法及试剂盒 |
KR101741859B1 (ko) * | 2009-06-22 | 2017-06-15 | 암젠 인크 | 화학적으로 조절된 산화환원 상태를 사용한 단백질의 재폴딩 |
ES2594365T3 (es) * | 2010-02-12 | 2016-12-19 | Intas Pharmaceuticals Ltd. | Formulación líquida de hormona estimulante del folículo |
EP2417982A1 (en) * | 2010-07-30 | 2012-02-15 | Ferring B.V. | Stabilization of gonadotropins |
-
2010
- 2010-07-30 EP EP10171428A patent/EP2417982A1/en not_active Withdrawn
-
2011
- 2011-07-21 JO JOP/2011/0231A patent/JO3229B1/ar active
- 2011-07-25 TW TW100126190A patent/TWI439283B/zh active
- 2011-07-28 KR KR1020187001203A patent/KR101991756B1/ko active IP Right Grant
- 2011-07-28 HU HUE11736111A patent/HUE033592T2/hu unknown
- 2011-07-28 NZ NZ606366A patent/NZ606366A/en unknown
- 2011-07-28 ES ES11736111.3T patent/ES2623634T3/es active Active
- 2011-07-28 CA CA2805864A patent/CA2805864A1/en active Pending
- 2011-07-28 CN CN201510508334.4A patent/CN105106939A/zh active Pending
- 2011-07-28 LT LTEP11736111.3T patent/LT2598160T/lt unknown
- 2011-07-28 PT PT117361113T patent/PT2598160T/pt unknown
- 2011-07-28 RU RU2012157154/15A patent/RU2574012C2/ru active
- 2011-07-28 MX MX2013000681A patent/MX341464B/es active IP Right Grant
- 2011-07-28 WO PCT/EP2011/062986 patent/WO2012013742A2/en active Application Filing
- 2011-07-28 AU AU2011284702A patent/AU2011284702C1/en active Active
- 2011-07-28 MX MX2016010733A patent/MX356951B/es unknown
- 2011-07-28 US US13/704,771 patent/US8993732B2/en active Active
- 2011-07-28 DK DK11736111.3T patent/DK2598160T3/en active
- 2011-07-28 BR BR112013002312-0A patent/BR112013002312B1/pt active IP Right Grant
- 2011-07-28 RS RS20170265A patent/RS55772B1/sr unknown
- 2011-07-28 EP EP11736111.3A patent/EP2598160B1/en active Active
- 2011-07-28 PL PL11736111T patent/PL2598160T3/pl unknown
- 2011-07-28 SI SI201131132A patent/SI2598160T1/sl unknown
- 2011-07-28 EP EP16195020.9A patent/EP3144010A1/en not_active Withdrawn
- 2011-07-28 NZ NZ628962A patent/NZ628962A/en unknown
- 2011-07-28 JP JP2013521146A patent/JP5860047B2/ja active Active
- 2011-07-28 KR KR1020137002504A patent/KR101820115B1/ko active Protection Beyond IP Right Term
- 2011-07-28 CN CN201180037221.0A patent/CN103052398B/zh active Active
- 2011-07-29 AR ARP110102766A patent/AR082776A1/es not_active Application Discontinuation
- 2011-07-30 SA SA114350786A patent/SA114350786B1/ar unknown
-
2012
- 2012-12-13 ZA ZA2012/09497A patent/ZA201209497B/en unknown
- 2012-12-24 IL IL223821A patent/IL223821A/en active IP Right Grant
-
2015
- 2015-02-25 US US14/631,382 patent/US9463221B2/en active Active
- 2015-12-17 JP JP2015245748A patent/JP2016102127A/ja active Pending
-
2016
- 2016-09-06 US US15/257,402 patent/US20170216405A1/en not_active Abandoned
-
2017
- 2017-01-03 IL IL249920A patent/IL249920A0/en unknown
- 2017-03-08 HR HRP20170386TT patent/HRP20170386T1/hr unknown
- 2017-11-02 JP JP2017212395A patent/JP6522711B2/ja active Active
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JO3229B1 (ar) | العمل على استقرار الهرمون المنبه للجريب | |
PH12016500105A1 (en) | Sulfonamides as modulators of sodium channels | |
MY170302A (en) | Process for the preparation of an aqueous solution comprising at least one earth alkali hydrogen carbonate and its use | |
PH12015502839A1 (en) | Antiviral compounds | |
MX354021B (es) | Derivados de 5-fluor-4-imino-3- (sustituido) -3,4-dihidropirimidin -2 (1h) ona. | |
AU2012265219A8 (en) | Compounds containing hydrido-tricyano-borate anions | |
GEP20227397B (en) | Inhibitors of influenza viruses replication | |
MY183312A (en) | Pharmaceutical formulation | |
PH12014501273A1 (en) | Intranasal dexmedetomidine compositions and methods of use thereof | |
IN2014CN04530A (es) | ||
JO3241B1 (ar) | عملية لتحضير محلول مائي يتألف على الاقل من كربونات هيدروجين الكيل خبأ واستخدامه | |
GB201113754D0 (en) | Composition | |
MX352563B (es) | Composiciones para el cuidado oral que contienen carbonato de calcio y silice. | |
IN2014MN00859A (es) | ||
MX340147B (es) | Composiciones farmacéuticas y nutracéuticas del ácido abscísico. | |
MX2013009259A (es) | Dispersiones oleosas de agroquimicos estables. | |
MX2010006787A (es) | Análogos halogenados de agentes anti-fibroticos. | |
MX2012010127A (es) | Derivados de aminoindanos, su preparacion y su aplicacion en terapeuticos. | |
MX337612B (es) | Composicion de oligosacaridos para prevenir o reducir el riesgo de sindrome metabolico. | |
TR201009168A2 (tr) | Suda dağılan sefpodoksim proksetil formülasyonları. | |
ECSP13013043A (es) | Composición oral líquida que comprende sodio divalproex y proceso para preparar la misma | |
IN2013MU02442A (es) | ||
WO2013064326A3 (de) | Arjunolsäure zur erhöhung der sebumproduktion | |
WO2011124861A3 (fr) | Utilisation de composés oligosaccharides dérivés du xanthane comme agent énergisant | |
UA96060C2 (ru) | Применение липофлавона как средства фригопротекторного действия |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
FG | Grant or registration |